Abstract: The present invention describes dual-modality probes. In particular, the present invention discloses hydroxyapatite specific multimeric bisphosphonate dual-modality MRI and optical probes.

Abstract: Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes an unchelated aminocarboxylate functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion is for binding to necrotic tissue in the subject.

Abstract: A compound of formula (I) is provided: wherein: R1 is an optionally substituted 2-(1-azathiaxanthone); each —R2 is independently of the formula —CH2—C(?O)—R4, wherein R4 is an amino acid or a salt thereof, attached to the remainder of R2 through the nitrogen atom of the amino group; and R3 is hydrogen or a C1-6 alkyl group; or wherein: R1 is an optionally substituted 2-(1-azaxanthone); each R2 is independently an optionally substituted glutaric or succinic acid, or a salt or ester thereof; and R3 is hydrogen or a C1-6 alkyl group.

Abstract: The invention relates to the use of manganese or iron complexes which, as well as a tetraoxolene unit, contain two macrocyclic, N-containing ligands, especially cyclen or cyclam ligands, in washing and cleaning compositions in the form of granules or powder or solution or suspension for bleaching of coloured stains both on textiles and on hard surfaces. The invention also relates to washing and cleaning compositions which comprise such complexes as bleach activators and to the use thereof for textile washing or for dishwashing detergents and other uses in personal care and other areas.

Abstract: A compound represented by formula (1): wherein Y1 to Y4 each independently represent any one of the following groups: in which R? represents a hydrogen atom or a monovalent hydrocarbon group; P1 to P4 each independently represents a group of atoms necessary for forming a heterocyclic ring together with each Y1 to Y4 and the two carbon atoms adjacent to Y1 to Y4, respectively; P5 and P6 each independently represents a group of atoms necessary for forming a cyclic skeleton together with the carbon atom to which Z1 bonds or Z2 bonds; P1 and P2, P2 and P6, P6 and P4, P4 and P3, P3 and P5, and P5 and P1 may further combine with each other to form a ring; Q1 and Q2 each independently represents a connecting group or a direct binding; and Z1 and Z2 each independently represent any one of the following groups; —NR?2, —OR?, —SR?, —PR?2 in which R? represents a hydrogen atom or a monovalent hydrocarbon group, and when plural R?s are present, these plural R?s may be the same or different from each other.

Abstract: The present invention relates to a triazanonane derivative indicated by the chemical formula 1 below, or a pharmaceutically acceptable salt thereof, and a method for preparing same, and the triazanonane derivative according to the present invention forms a complex with a metal-fluoride and displays an effect of increasing the labeling efficiency up to 78-90% when labeling F-18, thus enabling use in various radioactive medicine labeling (In the chemical formula 1, R1, R2, A. E. X, n and m are as defined in the present description.

Abstract: The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging.

Abstract: A compound represented by formula (1): wherein Y1 to Y4 each independently represent any one of the following groups: in which R? represents a hydrogen atom or a monovalent hydrocarbon group; P1 to P4 each independently represent a group of atoms necessary for forming a heterocyclic ring together with each of Y1 to Y4 and the two carbon atoms adjacent to each of Y1 to Y4, respectively; P5 and P6 each independently represent a group of atoms necessary for forming a cyclic skeleton together with the carbon atom to which Z1 bonds or Z2 bonds and the two carbon atoms adjacent to the carbon atom to which Z1 bonds or Z2 bonds; P1 and P2, P2 and P6, P6 and P4, P4 and P3, P3 and P5, and P5 and P1 may further combine with each other to form a ring; Q1 and Q2 each independently represent a connecting group or a direct binding; and Z1 and Z2 each independently represent any one of the following groups; —NR?2, —OR?, —SR?, —PR?2 in which R? represents a hydrogen atom or a monovalent hydrocarbon group,

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent including a gadolinium complex, more particularly to a DO3A-tranexamic acid or its ester compound, which is represented by the Chemical Formula 1. A DO3A-tranexamic acid or its ester compound may be prepared according to the present invention and a gadolinium complex may be prepared using the compound. An MRI contrast agent including the gadolinium complex prepared according to the present invention as an active ingredient has higher relaxivity as compared to the currently commercially available contrast agent. In addition, the MRI contrast agent according to the present invention has bifunctionality of liver-specific and blood-pool contrasting effect.

Abstract: A stabilized nano-Fe6-iron-crown ether complex is formed by preparing a solution of an iron salt and an oligomer crown compound in dialkylamine or diethylamine. Sodium tetrahydroboron (NaBH4) and dialkylamine or ethylendiamine are added at a temperature of 0-10° C. The mixture is heated to room temperature and boiled, thereby converting the formed iron (II)—borhydride complex (Fe(BH4)2) to a crown ether—iron-hydride complex [CWFe06].(2H)6. At higher temperature this last complex is converted to the Fe06-crown nanocomposite complex. The prepared nanoparticle Fe6° complex may be stabilized by inclusion into a cavity of a macrocyclic compound, and may be (1) added to diesel fuel to reduce NOx emissions upon combustion of that fuel; (2) added to lubricating oils as an anti-corrosion additive; and (3) used as an additive to secondary recovery processes within liquid hydrocarbon formations to increase the sweep efficiency and recovery factor of water-flooding operations.

Abstract: The present invention relates to a X-ray and gamma-photon activable compound responding to the following formula (I). The present invention also relates to methods of synthesizing a compound according to the invention, and to an aqueous or physiological solution comprising at least one compound of the invention. The present invention also concerns a method of liberating a biologically active compound, said method involving the step of irradiating at least one compound, or at least one aqueous or physiological solution according to the invention. Finally, the present invention relates to a pharmaceutical composition comprising at least one compound, or at least one aqueous or physiological solution according to the invention.

Abstract: Disclosed herein are the methods and compositions for the improved synthesis of texaphyrin metal complexes. The improved synthesis results in high-purity compositions of texaphyrin metal complexes in which more than about 98% of the texaphyrin metal complexes in the composition have the same structure and/or the same molecular weight. Further described herein are pharmaceutical compositions comprising such high-purity compositions, and the use of such high-purity compositions in the treatment of cancer and cardiovascular diseases and disorders.

Abstract: Described are bifunctional NOTA-based derivatives capable of conjugating with alginate and with metal ions, as well as NOTA-alginate conjugates which can be labeled with stable or radioactive metal ions. Also described are conjugation methods of the bifunctional NOTA-based linker with alginate, and methods of using radiometal-labeled NOTA-alginate conjugates or other radio-labeled alginate conjugates as imaging reagents.

Abstract: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.

Abstract: The invention relates generally to optical data storage media, and more specifically, to holographic storage media. In one embodiment, an optical storage medium composition includes a polymer matrix. Disposed within the polymer matrix is a reactant capable of undergoing a modification that alters the refractive index of the composition upon receiving an energy transfer from an excited sensitizer. A non-linear sensitizer is also disposed within the polymer matrix, and the sensitizer includes a metal-substituted subphthalocyanine (M-sub-PC) reverse saturable absorber configured to become excited upon exposure to light beyond an intensity threshold at approximately 405 nm and configured to transfer energy to the reactant.

Abstract: A process is described for preparation of the gadolinium complex of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane “gadobutrol=Gadovist®” in a one-pot process by means of DMF acetal and N-methylimidazole. Gadovist is a gadolinium-containing contrast agent for nuclear spin tomography and has been approved since 2000 in Germany in the indication “contrast amplification in cranial and spinal magnetic resonance tomography”.

Abstract: The present invention relates generally to methods and compositions for targeting of intracellular molecules involved in proliferation and protein synthesis of activated cells using polyanionic multivalent macromolecules. In particular aspect, multiple sulfate groups linked to polyol are specifically targeted to the cytoplasm and nucleus of proliferating and activated cells. The invention further comprises novel polyanionic macromolecular compounds and formulations.

Abstract: Disclosed herein are the methods and compositions for the improved synthesis of texaphyrin metal complexes. The improved synthesis results in high-purity compositions of texaphyrin metal complexes in which more than about 98% of the texaphyrin metal complexes in the composition have the same structure and/or the same molecular weight. Further described herein are pharmaceutical compositions comprising such high-purity compositions, and the use of such high-purity compositions in the treatment of cancer and cardiovascular diseases and disorders.

Abstract: A macrocycle based on ?-diketimines, a process for preparing the inventive macrocycle, an uncharged macrocyclic dimetallic complex based on the inventive macrocycle, and a process for preparing the uncharged macrocyclic dimetallic complex, the use of the uncharged macrocyclic dimetallic complex as a polymerization catalyst in the polymerization of carbon dioxide with one or more epoxides, a process for preparing polycarbonates by reacting carbon dioxide with one or more epoxides in the presence of the inventive uncharged macrocyclic dimetallic complex, and a polycarbonate prepared by the process according to the invention.

Abstract: The present invention concerns synthesising manganese complexes in essentially non-aqueous solutions.

Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Abstract: The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging.

Abstract: According to the present invention, a novel polyazamacrocyclic compound which is used as a bifunctional chelating agent (BFC) can be synthesized selectively and in high yield. The novel polyazamacrocyclic compound synthesized by this method chelates with metals and thus can be conjugated with bioactive molecules such as peptides, and can be used in the diagnosis and treatment of medical conditions.

Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.

Abstract: The invention relates to compositions of DOTA derivative compounds, lanthanoid-DOTA derivative molecular complex, and lanthanoid-complex encapsulated solid lipid particles or capsules, and methods of making and using the compositions. The solid lipid particles or capsules contain micelle cores stabilized by a hyperbranched polymer shell based from a crosslinked DOTA derivative compound or crosslinked lanthanoid-DOTA derivative complex. These solid lipid particles or capsules can be used in various applications, such as contrast agents or drug delivery vehicles.

Abstract: To provide nitrogen-containing aromatic compounds with excellent oxygen reduction activity, metal complexes containing them, and catalysts and electrodes employing the same, the present invention provides an aromatic compound satisfying the following conditions (a) and (b): (a) It has 2 or more structures surrounded by at least 4 coordinatable nitrogen atoms (which structures may be the same or different), (b) At least one of the nitrogen atoms composing the structure is a nitrogen atom in a 6-membered nitrogen-containing heterocyclic ring.

Abstract: The present invention relates to manganese(II) chelates. The invention also relates to said manganese(II) chelates attached to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).

Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.

Abstract: Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.

Abstract: The invention relates to a method for producing manganese complex compounds of the general formula (1), wherein M, X, L, z, Y and q are defined as in claim 1.

Abstract: The present invention comprises a process to synthesise metal complexes from macrocyclic polyazapyridinophane compounds characterised as superoxide dismutase enzyme (SOD) mimetics. Furthermore, the present invention relates to the macrocyclic polyazapyridinophane compounds themselves, the metal complexes formed from these and to their use in the treatment of diseases the aetiology of which is based on disturbances in the activity of, or a deficiency in endogenous SOD, mainly as anti-inflammatories, analgesics and antioxidant compounds providing protection against cellular oxidative stress.

Abstract: A pharmaceutical composition is provided that is useful for reducing sodium in the bloodstream of animals. In some embodiments, the pharmaceutical composition comprises a high-ion-affinity part and a substrate part. Additionally, methods of using the pharmaceutical composition and methods of treating diseases with the pharmaceutical composition are disclosed.

Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

Abstract: Improved methods for synthesizing bifunctional chelates of tetraazamacrocycle derivatives and intermediates thereof are disclosed as well as novel tetraazamacrocycle derivatives and intermediates thereof.

Abstract: The invention provides a compound comprising a xanthone or thiaxanthone sensitizing moiety, capable of coordinating to a lanthanide ion by the nitrogen atom of an integral pyridyl group or a related group able to bind a lanthanide ion.

Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.

Abstract: An isolated conformational isomer of a bifunctional chelating agent of the formula (I): wherein the variables Q1 and Q2 are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a stable or radioactive metal; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate.

Abstract: This invention relates to biochemistry and magnetic resonance imaging.

Abstract: The present invention concerns a Ga68 complex of formula FOLATE-(LINKER)i-NOTA-Ga68 in which: 1) FOLATE is a folate compound or a derivative thereof capable of targeting a folate receptor, 2) NOTA is a chelate capable of complexing Ga68 having a NOTA scaffold or derivatives thereof 3) LINKER is a chemical group linking FOLATE and NOTA 4) i is an integer chosen between 0 and 1 wherein NOTA is complexing Ga68

Abstract: Conjugates of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes with a variety of conjugating members are used in the formation of dinuclear metal complexes which bind to phosphate esters. By virtue of their conjugated forms, the complexes are incorporated into chromatographic media, affinity binding reagents, and dyes, which make the complexes useful in a wide range of assays, separations, and purifications. In addition, dinuclear metal complexes of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes that are not so conjugated are used in the detection of phosphate esters of biological species by either MALDI-TOF mass spectrometry or by dye displacement.

Abstract: Lanthanide chelates derived from diazacrown ethers having two ethyliminodiacetic acid side chains have increased ability to bind lanthanide ions.

Abstract: The present invention relates to novel amino acid derivatives containing heterocyclic chelating residues thereof; radioactive or nonradioactive metal complexes thereof; methods for preparation thereof; and apyrogenic and sterile preparative kits of the composition for targeting cancer cells. The compounds of the present invention can easily be taken up to cancer cells as they contain amino acid residues thereof; radioactive or nonradioactive metals can be labeled easily as they contain heterocyclic chelating residues thereof; cancer lesion can be imaged easily by targeting using the present invention.

Abstract: A compound represented by the following formula (1): wherein, Y1, Y2, Y3 and Y4 represent a group represented by any of the above formulae; P1, P2, P3 and P4 are an atomic group required for forming an aromatic heterocyclic ring; P5 and P6 are an atomic group required for forming an aromatic ring; Z1 and Z2 represent OR?, —SR? or —NR?2, wherein R? represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; Q1 and Q2 represent a direct bond or a linking group; a P1-containing ring and a P2-containing ring are bonded to form Q1-containing fused structure; a P3-containing ring and a P4-containing ring are bonded to form Q2-containing fused structure; can be used as a ligand of a metal complex, and the metal complex is useful for a catalyst.

Abstract: The invention relates to novel electropolymerisable monomers which are to be polymerised in an aqueous solution and comprise: an electropolymerisable pattern selected from acetylene, pyrrols, thiophenes, indols, anilines, azines, p-phenylene vinylenes, p-phenylenes, pyrenes, furanes, selenophenes, pyrridazines, carbazoles, acrylates, methacrylates and the derivatives thereof, and a metalloporphyrine which is substituted by at least two ionised or ionizable entities in an aqueous solution. The invention also relates to a method for the polymerization of such monomers, to the electroactive probe that can be obtained by the polymerization of such monomers, and to a method for detecting a target ligand in a biological sample using one such electroactive probe.

Abstract: A conjugate comprising a dye-labeled microporous crystal, a stop-cock moiety, and covalently bound thereto an affinity binding agent is disclosed. The dye-labeled microporous crystal is a zeolite crystal, such as a zeolite L crystal, having a large number of channels in its interior into which the dye is loaded. The stop-cock moiety can be functionalized with an amino group to which a carboxyester group can be attached. The affinity binding agent allows for the binding to a biological moiety. The conjugate of the moiety can be used in in-vivo and/or in-vitro imaging applications.

Abstract: Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene. The chelates may be used as an intravascular contrast agent for MRI. Certain embodiments demonstrate enhanced relaxivity and good levels of signal enhancement.

Abstract: Formula (I) compounds are described where the groups are as defined here below, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particularly for the diagnosis and therapy of pathological conditions such as tumours.

Abstract: The invention provides compounds that comprise a 4?-thio nucleoside that is a derivative of 4?-thiothymidine or 4?-thio-2?-deoxyuridine comprising a positron or single photon emitting radioisotope or corresponding non-radioactive isotope attached via a triazole link to the N-3 position. Methods for preparing such compounds and uses of the compounds in medicine are also provided.

Abstract: Compositions for producing multi-chromic (“color”) magnetic resonance images (MRI). The compositions for use as MRI imaging agents include a magnetic resonance imaging tracer having a signal emitter, such as a 19F imaging tracer (19FIT), conjugated with a magnetic signal modulator, such as a paramagnetic functional group or a paramagnetic ion. The 19FIT and the signal modulator (M) are joined covalently by a chelator such as DOTA, forming a nanometer-sized fluorinated paramagnetic complex 19FIT-DOTA-M. Other signal emitters, such as 31P imaging tracer (31PIT), can also be modulated using this strategy (i.e., 31PIT-DOTA-M) to generate multi-chromic 31P MRI or MRS.

Abstract: The invention describes crown ether chelators, including crown ethers having the formula: